The Drug-Induced Respiratory Disease Website and App
Frequency - Incidence
Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases
Evidence level/grade
Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic
ANCA positivity. Subclinical or with clinical manifestations
Publications
Epitope analysis of anti-myeloperoxidase antibodies in propylthiouracil-induced antineutrophil cytoplasmic antibody-associated vasculitis.
Arthritis research & therapy 2013;15;R196 — 2013 — R196
Propylthiouracil and antineutrophil cytoplasmic antibody associated vasculitis: the detective finds a clue.
Seminars in arthritis and rheumatism 2006 Aug;36;1-3 — 2006 Aug — 1-3
Occurrence of antineutrophil cytoplasmic antibodies and associated vasculitis in patients with hyperthyroidism treated with antithyroid drugs: A long-term followup study.
Arthritis and rheumatism 2005 Feb 15;53;108-13 — 2005 Feb 15 — 108-13
Anti-neutrophil cytoplasmic autoantibody (ANCA) profiles in propylthiouracil-induced lupus-like manifestations in monozygotic triplets with hyperthyroidism.
Scandinavian journal of rheumatology 2002;31;46-9 — 2002 — 46-9
Frequency of appearance of myeloperoxidase-antineutrophil cytoplasmic antibody (MPO-ANCA) in Graves' disease patients treated with propylthiouracil and the relationship between MPO-ANCA and clinical manifestations.
Clinical endocrinology 2001 May;54;651-4 — 2001 May — 651-4